JP2018514590A5 - - Google Patents

Download PDF

Info

Publication number
JP2018514590A5
JP2018514590A5 JP2018508624A JP2018508624A JP2018514590A5 JP 2018514590 A5 JP2018514590 A5 JP 2018514590A5 JP 2018508624 A JP2018508624 A JP 2018508624A JP 2018508624 A JP2018508624 A JP 2018508624A JP 2018514590 A5 JP2018514590 A5 JP 2018514590A5
Authority
JP
Japan
Prior art keywords
retinal
disease
composition
eye
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018508624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018514590A (ja
JP6884755B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/030098 external-priority patent/WO2016178993A1/en
Publication of JP2018514590A publication Critical patent/JP2018514590A/ja
Publication of JP2018514590A5 publication Critical patent/JP2018514590A5/ja
Priority to JP2021080927A priority Critical patent/JP2021120400A/ja
Application granted granted Critical
Publication of JP6884755B2 publication Critical patent/JP6884755B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018508624A 2015-05-01 2016-04-29 ペプチド組成物および使用方法 Active JP6884755B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021080927A JP2021120400A (ja) 2015-05-01 2021-05-12 ペプチド組成物および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562155711P 2015-05-01 2015-05-01
US62/155,711 2015-05-01
PCT/US2016/030098 WO2016178993A1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021080927A Division JP2021120400A (ja) 2015-05-01 2021-05-12 ペプチド組成物および使用方法

Publications (3)

Publication Number Publication Date
JP2018514590A JP2018514590A (ja) 2018-06-07
JP2018514590A5 true JP2018514590A5 (cg-RX-API-DMAC7.html) 2019-05-30
JP6884755B2 JP6884755B2 (ja) 2021-06-09

Family

ID=57217771

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018508624A Active JP6884755B2 (ja) 2015-05-01 2016-04-29 ペプチド組成物および使用方法
JP2021080927A Pending JP2021120400A (ja) 2015-05-01 2021-05-12 ペプチド組成物および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021080927A Pending JP2021120400A (ja) 2015-05-01 2021-05-12 ペプチド組成物および使用方法

Country Status (21)

Country Link
US (5) US10508134B2 (cg-RX-API-DMAC7.html)
EP (3) EP4623925A3 (cg-RX-API-DMAC7.html)
JP (2) JP6884755B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240046280A (cg-RX-API-DMAC7.html)
CN (2) CN113651873B (cg-RX-API-DMAC7.html)
AU (1) AU2016258837B2 (cg-RX-API-DMAC7.html)
CA (1) CA2984154A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124911T1 (cg-RX-API-DMAC7.html)
DK (1) DK3288379T3 (cg-RX-API-DMAC7.html)
EA (2) EA035293B1 (cg-RX-API-DMAC7.html)
ES (1) ES2906173T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220138T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057883T2 (cg-RX-API-DMAC7.html)
LT (1) LT3288379T (cg-RX-API-DMAC7.html)
MX (1) MX387317B (cg-RX-API-DMAC7.html)
PL (1) PL3288379T3 (cg-RX-API-DMAC7.html)
PT (1) PT3288379T (cg-RX-API-DMAC7.html)
RS (1) RS62866B1 (cg-RX-API-DMAC7.html)
SI (1) SI3288379T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200069T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016178993A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3288379T1 (sl) 2015-05-01 2022-06-30 Onl Therapeutics, Inc. Peptidne sestave in načini uporabe
WO2019183246A1 (en) * 2018-03-20 2019-09-26 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
US20210121534A1 (en) * 2018-06-19 2021-04-29 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
CN115119501A (zh) * 2019-12-18 2022-09-27 细胞疗法有限责任公司 包含神经营养剂、凋亡信号传导片段抑制剂(FAS)或FAS配体(FASL)抑制剂、肿瘤坏死因子-α(TNF-α)或TNF受体抑制剂、线粒体肽、寡核苷酸、趋化因子抑制剂或半胱氨酸-天冬氨酸蛋白酶抑制剂的药物递送系统
US20240285724A1 (en) * 2021-06-15 2024-08-29 Onl Therapeutics, Inc. Methods and compositions for treating ocular disorders and diseases
AU2022311780A1 (en) * 2021-07-13 2024-02-08 Onl Therapeutics, Inc. Methods and compositions for improving visual function in ocular diseases and disorders
EP4456908A4 (en) * 2021-12-27 2025-08-27 Onl Therapeutics Inc SFASL TO INHIBIT RPE CELL DEATH AND ASSOCIATED DISORDERS
EP4565595A2 (en) * 2022-08-05 2025-06-11 ONL Therapeutics, Inc. Peptide compositions and methods of use
EP4565596A1 (en) * 2022-08-05 2025-06-11 ONL Therapeutics, Inc. Peptide compositions and methods of use
EP4698204A1 (en) * 2023-04-19 2026-02-25 ONL Therapeutics, Inc. Methods and compositions for treating rnfl thinning

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5532123A (en) * 1990-07-11 1996-07-02 New York University Receptor-type phosphotyrosine phosphatase-γ
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
JP3187201B2 (ja) * 1992-05-14 2001-07-11 三共株式会社 C末端にプロリンアミドを有するペプチドの製法
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
JP3460863B2 (ja) 1993-09-17 2003-10-27 三菱電機株式会社 半導体装置の製造方法
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US6001962A (en) * 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US6363020B1 (en) 1999-12-06 2002-03-26 Virage Logic Corp. Architecture with multi-instance redundancy implementation
US6480428B2 (en) 2000-12-19 2002-11-12 Winbond Electronics Corporation Redundant circuit for memory device
CA2561809A1 (en) * 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties
WO2005117940A2 (en) 2004-04-23 2005-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Cell death modulation via antagonists of fasl and fas activation
SI1885336T1 (sl) * 2005-05-10 2009-08-31 Alcon Inc Suspenzijske formulacije, ki obsegajo aktivno sestavino, poloksamerni ali meroksapolni surfaktant in glikol, in njihova uporaba za pripravo zdravila za zdravljenje oftalmičnih motenj
US8067433B2 (en) * 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
AU2006320327A1 (en) 2005-12-01 2007-06-07 Duke University Compounds and methods for inhibiting apoptosis
EP2222696A1 (en) * 2007-12-21 2010-09-01 Stryker Corporation Bmp mutants with decreased susceptibility to noggin
EP2403937B1 (en) 2009-03-03 2015-05-06 The Regents of the University of Michigan Use of met peptide for inhibiting photoreceptor apoptosis
EA201171188A1 (ru) * 2009-03-30 2012-05-30 Сантен Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое средство против болезни сетчатки и способ профилактики или лечения болезни сетчатки с использованием jnk (c-jun-аминоконцевая киназа)-ингибиторного пептида, а также применение указанного пептида
JP2013501064A (ja) * 2009-08-04 2013-01-10 アミラ ファーマシューティカルス,インコーポレーテッド リゾホスファチジン酸受容体アンタゴニストとしての化合物
JP6091435B2 (ja) 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス(aav)ベクターを用いたタンパク質の送達
TW201542231A (zh) * 2011-06-06 2015-11-16 Kineta One Llc 以shk為主之醫藥組合物及其製備方法及用途
WO2013106909A1 (en) 2012-01-18 2013-07-25 Governing Council Of The University Of Toronto Novel peptides and methods and uses thereof for preventing retinal disorders
WO2013191352A1 (en) * 2012-06-21 2013-12-27 Hanall Biopharma Co., Ltd. New uses of modified human tumor necrosis factor receptor-1 polypeptide
WO2014071183A1 (en) * 2012-11-02 2014-05-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
US20180024145A1 (en) 2015-02-05 2018-01-25 Immunarray USA, Inc. Methods and compositions for diagnosing brain injury or neurodegeneration
US20190201500A1 (en) 2015-05-01 2019-07-04 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
SI3288379T1 (sl) 2015-05-01 2022-06-30 Onl Therapeutics, Inc. Peptidne sestave in načini uporabe
US20190240353A1 (en) 2016-07-05 2019-08-08 University Of Massachusetts Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma
JP7009517B2 (ja) 2017-06-21 2022-01-25 ギリアード サイエンシーズ, インコーポレイテッド Hiv gp120およびcd3を標的とする多重特異性抗体
WO2019183246A1 (en) 2018-03-20 2019-09-26 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
US20210121534A1 (en) 2018-06-19 2021-04-29 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension

Similar Documents

Publication Publication Date Title
HRP20220138T1 (hr) Peptidni pripravci i postupci uporabe
JP5934229B2 (ja) 眼血管疾患の処置のための投与計画
JP2020530470A5 (cg-RX-API-DMAC7.html)
KR20160126983A (ko) 안내 혈관신생 및/또는 누출 치료용 조성물 및 방법
JP2019038825A (ja) 治療用化合物の結晶形態及びその使用
JP2009511632A5 (cg-RX-API-DMAC7.html)
JP2015520130A5 (cg-RX-API-DMAC7.html)
JP2019510078A5 (cg-RX-API-DMAC7.html)
JP2017527600A5 (cg-RX-API-DMAC7.html)
RU2019114205A (ru) Способы лечения глазного заболевания с применением ингибиторов csf-1r
JP2019534269A5 (cg-RX-API-DMAC7.html)
KR20120081585A (ko) 안질환을 치료하기 위한 이소티오졸
AU2004296748B2 (en) Prevention and/or reduction of photoreceptor degeneration with retinoids
JP2014521648A (ja) 網膜疾患を治療するための4−ブロモ−n−(イミダゾリジン−2−イリデン)−1h−ベンゾイミダゾール−5−アミンを含む医薬組成物
US20110257186A1 (en) Compositions and methods for treating visual disorders
JP2024512028A (ja) N-オキソピリジン化合物の発生を抑制する眼疾患の予防または治療用点眼組成物
JP2013523892A5 (cg-RX-API-DMAC7.html)
US10253045B2 (en) Crystalline forms of a therapeutic compound and uses thereof
MXPA06006024A (es) Prevencion y/o reduccion, con retinoides de la degeneracion de fotorreceptores